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1. MAGYAR NYELVŰ ÖSSZEFOGLALÓ 
Az emberi szem nagy tárházat kínál szövetregeneráció és sejtterápia szempontjából. 
Különösen az, hogy a cornea szövet limbális őssejteket (LESC) tartalmaz.  
Génexpresszión alapuló microarray segítségével azonosított molekuláris markerek és 
upstream regulátorok, azok fehérje szinten történő megerősítése az LESC-k könnyebb 
azonosítását, a sejtekhez kötődő jelátviteli útvonalak pontosabb megismerését teszi 
lehetővé, amely a szembetegségek hatékonyabb sejtterápián alapuló gyógyításához is 
vezethet. Annak ellenére, hogy a szemben számos őssejt tulajdonságokkal rendelkező 
sejttípus található, betegségek vagy a megváltozott környezet által felborított egyensúly 
gyulladásos és fibrovaszkuláris folyamatok kialakulásához vezethet, csakúgy, mint 
proliferatív diabeteszes retinopathia (PDR) esetén. A PDR-ben található 
fibrovaszkuláris epiretinális membránok létrehozásában, illetve kialakításában részt 
vevő sejtek sejtfelszíni markerek alapján nem kellően leírtak és nem ismert ezen sejtek 
immunválaszban és angiogenezisben betöltött szerepe sem.  
Az LESC-k gén expressziós transzkripciós profilját hasonlítottuk differenciált cornea 
epithel sejtek (CEC)-khez. A két sejttípus között 1830 gén expressziójában találtunk 
több mint kétszeres emelkedést illetve csökkenést. Számos a sejtmozgásban (381), 
sejtosztódásban (567), fejlődésben (552), sejthalálban és túlélésben (520) és a sejt-sejt 
közötti jelátvitelben (290) szereppel bíró molekulát azonosítottunk, amelyek a LESC-k 
legfontosabb biológiai funkciójában is részt vesznek. Számos a sejtfelszínen is 
kifejeződő molekulát áramlási citometriás mérésekkel is igazolni tudtunk. A teljes 
transzkripciós profilból kiválogatva a géneket speciális csoportokba rendezve 
analizáltuk, az őssejt jelleg fenntartásában, differenciációban, sejtadhézióban, 
angiogenezisben betöltött szerepük alapján, a citokineket és növekedési hormonokat 
kódoló génekkel egyetemben. Az eredmények azt mutatják, hogy a LESC-k nem csak 
az epithel irányú differenciálódásban és szövet regenerációban, hanem az angiogenezis 
és az extracelluláris matrix kialakításának szabályozásában is kulcs szerepet játszanak. 
Az őssejt jelleg fenntartásában, a differenciálódásban és az angiogenezisben is 
fontosnak találtunk néhány gyulladást keltő citokint. Ezek közül az interleukin-6 és az 
interleukin-8 szerepelt a legtöbbet az említett biológiai folyamatokhoz kapcsolódó 
útvonalakban; a két citokin jelenlétét a LESC tenyészetek felülúszójában is igazolni 
tudtuk. 
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Az fvERM–ből kinövő, osztódó sejtek ex vivo körülmények között egy sejtrétegű 
tenyészetet hoztak létre. Ezek a sejtek negatívak voltak néhány endotheliális sejt 
markerre (CD31, VEGFR2), részben pozitív hematopoietikus - (CD34, CD47) és a 
mesenchymalis őssejt markerekre (CD73, CD90/Thy-1, PDGFRβ), azonban nem 
fejeztek ki CD105 a membránjukban. Az eddig nem közölt CD146/MCAM és 
CD166/ALCAM markerek alacsony illetve magas expressziós szintet mutattak a 
sejttenyészetben. TNFα kezelés hatására 11 angiogenezisben szerepet játszó factor 
szekrécióját (DPPIV/CD26, EG-VEGF/PK1, az ET -1, az IGFBP-2 és 3, IL-8/CXCL8, 
MCP-1/CCL2, MMP-9, PTX3/TSG-14, szerpin E1/PAI-1, szerpin F1/PEDF, TIMP-1 
és a TSP -1) mutattuk ki. A membránokból kinövő sejtek mechano-stimuláció hatására 
intracelluláris Ca2+ növekedéssel válaszoltak, amely viabilitásuk mellett felveti a 
mechanizmus esetleges szerepét a fvERM-hez kapcsolódó húzóerő által kiváltott retina 
leválásnak. 
Összefoglalva elmondhatjuk, hogy a LESC-k fontos szerepet játszanak az epithel 
irányú differenciálódásban, a szövetregenerációban, angiogenezisben és az ECM 
felépítésében. A PDR-ben szenvedő betegek fvERM membránjaiban lévő sejtek kevert 
fenotípust mutattak, nem lehetett egyértelműen a hematopoietikus, mesenchymális 
őssejt vagy progenitor sejt eredetet bizonyítani. A sejtek nagy osztódási potenciállal 
rendelkeztek, TNFα hatására gyulladásos és angiogén molekulákat termeltek. 
Működőképességük és viabilitásuk a mechano-stimulációra végbemenő calcium 
változásokban is tükröződött, amely a PDR-ben is végbemenő, fvERM általi húzóerő ex 
vivo kísérletes modellje lehet.  
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2. INTRODUCTION 
 
The eye is the most important sensory organ of our body. It can be divided into 
two large parts: the anterior segment covered mainly by the cornea, and the posterior 
segment wrapped up by the sclera. The cornea and the sclera are connected by a ring 
called the limbus (Figure 1). The protective and refractive function of the outermost 
surface of the eye is provided by the highly transparent and strong tissue - the cornea. 
During organogenesis this is the last part of the eye which is formed from the neural 
crest
1
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of the human eye 
A. Simplified schematic layers of the eye. The anterior segment is covered by the 
highly transparent and impermeable cornea, B. The limbus connects the cornea and the 
sclera together. (Modified pictures from http://healthfavo.com/human-eye-diagram.html, Health, 
Medicine and Anatomy Reference Pictures) 
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The cornea has a rather complex structure compared to other body surface 
tissues. A distinct acellular Bowman’s layer and acellular collagenous basement 
(Descemet’s) membrane separate the single inner cell layer of the cornea – the cornea 
endothelial cells, from the stroma, which is the biggest middle thick layer of the tissue. 
The cornea endothelial cells play critical role in the maintenance of correct hydration of 
the corneal stroma. The latter contains collagen rich extracellular matrix with 
embedded, resting flattened stromal keratocytes and fibroblast-like cells. The surface of 
the cornea consists of stratified squamous epithelium acting as protective, impermeable 
barrier of the eye (Figure 2). Due to persistent physical, microbial, chemical and 
biological damage, the central corneal epithelial cells (CECs) need to be continuously 
replaced from the limbal epithelial stem cells (LESCs).  
Animal studies have shown that CECs can differentiate from approximately 100 
progenitor cells, which means there is extremely low frequency of LESCs in the limbal 
tissue
2
. Stem cells and progenitors cells usually need special niches to maintain their 
multipotency and proliferation potential. In humans, only six limbal epithelial crypts 
have been identified as niches of the LESCs - they located at the basal cell layer of the 
limbal epithelium at the corneo-scleral junction
3-8
. These data have further been 
strengthened by findings from animals as well
7
. The limbal epithelial crypts provide a 
concentrated and safe place for harboring LESCs, and also, a rich vascular supply with 
growth factors and metabolites for their sustained persistence
9-14
 (Figure 2). The stem 
cell niches are important because they block cell division in both the corneal and 
conjunctival epithelium, therefore act as border guards delineating the two distinct 
tissues. As mentioned before, the CECs differentiate from LESCs which can undergo 
asymmetric division and give rise to transient amplifying cells (TACs). TACs 
proliferate in the basal layer of the limbus before they differentiate and then migrate 
centripetally and superficially while becoming more and more differentiated and post-
mitotic
15,16
. During the differentiation from TACs into mature CECs, the cells lose their 
ability to proliferate
12,17
. The function of LESCs is not only in providing a source for 
epithelial cells’ differentiation, but also, they play a key role in the maintenance of a 
balanced immunological state in the cornea and corneal tissue regeneration as well
18
.   
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Figure 2. Structure of the cornea and the limbal stem cell niche 
A. The five layers of the cornea. The top layers are the stratified squamous epithelium 
which is separated by the Bowman’s layer from the thicker stroma. The latter is highly 
collagenous with resting keratocytes and fibroblasts as well. Descemets’s membrane 
separates the stroma from the cornea endothelial monolayer. (Note: the newly 
discovered sixth, Dua’s layer, is not mentioned here for simplicity)19. B. LESCs are 
located at the basal layer of the limbus. The niche made by limbal fibroblast-like cells 
and blood vessels provide the important metabolites and cytokines for the LESCs. 
These cells then differentiate into TACs which migrate laterally and horizontally, 
differentiating into non-proliferative, central corneal epithelial cells.  
(Modified image based upon the work of Secker GA, Daniles JT: Limbal epithelial stem cells of the 
cornea
5
, and Li W et al.: Niche regulation of corneal epithelial stem cells at the limbus
14
; downloaded 
from http://www.stembook.org/node/588) 
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Injuries - traumatic, chemical and iatrogenic, or diseases of the LESCs - inborn 
or acquired, can all lead to partial or total LESC deficiency (LESCD) or corneal 
neovascularization accompanied by inflammation. In LESCD, the failure of corneal re-
epithelialization and the invasion of blood vessels cause a painful state which can lead 
to blindness. LESCD can be treated with autologous limbal graft transplantation from a 
healthy donor eye, if available, however, such treatment does not provide guarantee for 
the functionality of the graft itself
20,21
. Despite intense research in this field in the last 
couple of years, the real phenotype and biological behavior of LESCs is still not known 
in detail. 
The appearance of new vessels in the cornea during LESCD can be based upon 
immunological and angiogenic processes interplaying in the tissue affected. The 
formation of new vessels from existing capillaries is a complex and strictly controlled 
multistep process
22,23
. The proliferation and migration of vessel wall-derived 
endothelial cells is usually limited, therefore, neovascularization is mainly depended on 
the circulating or tissue resident endothelial progenitor cells (EPCs), and the balance of 
pro- or anti- angiogenic factors released by the activated cells surrounding them
23
. 
Neovascularization plays a key role in wound healing and tissue regeneration, as well 
as various ischemic and inflammatory diseases
23
. Pathological neovascularization is a 
hallmark of many ocular diseases such as age-related macular degeneration (AMD), 
diabetic macular edema (DME), neovascular glaucoma, corneal neovascularization, 
pterygium and proliferative diabetic retinopathy (PDR)
23,24
. 
PDR is the most advanced stage of the diabetic retinopathy (DR) caused by 
diabetes mellitus. The disease destroys the micro- and macro- vasculature in the 
posterior segment of the eye, and is frequent in patients having the disease for 10 or 
more years
25
. Based upon the Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR), the 10-year incidence of new retinopathy was 89% in the group diagnosed 
before age 30 years, 79% in the insulin-taking group of 30 years or older and 67% in 
the non-insulin-taking group
26
. The disease itself affects those individuals who are in 
their most productive years, therefore, it poses great socio-economic burden on the 
society
27
. The symptoms of the disease are visual field defects and blurred vision 
(Figure 3A), while funduscopy can reveal fibrovascular membranes and 
neovascularizations with cotton wool spots, flame- and dot-blot hemorrhages as well as 
hard exudates (Figure 3B). The pathophysiology of PDR is based upon the 
neovascularization formation in the retina, followed by formation of fibrovascular 
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proliferations which can lead to tractional retinal detachment causing blindness
28
 
(Figure 3C).  
The molecular background of DR remains still unclear. Several hypotheses 
regarding growth hormone involvement, sluggish platelet and erythrocyte circulation 
with consequent focal capillary occlusions and retinal ischemia, activation of aldose 
reductase pathway and consequent damage of intramural pericytes that altogether cause 
saccular outpunching of capillaries, ruptured microaneurysms, intra- and epi- retinal 
hemorrhages and exudation, have all been described as causes of DR
29,30
 
The pro-inflammatory cytokines have been known stimulators of the production 
of angiogenic and vasoproliferative factors. Whenever pro-angiogenic factors are mixed 
with an ischemic environment, they can provoke neovascularizations in the retina, 
which can further lead to proliferations and penetration through the internal limiting 
membrane, the final product being fibrovascular epiretinal membranes (fvERMs) 
formation between the retina and the posterior hyaloid face. Strengthening this 
hypothesis are the high levels of pro-inflammatory cytokines such as interleukin 6 (IL- 
6), IL-8 and tumor necrosis factor alpha (TNFα) that have been measured in samples 
from the vitreous body of patients with PDR
31,32
. So far, the origin of the cells found in 
fvERMs has not been well understood. Although attempts to assess the presence of 
CD34
+
 and CD31
+
 vascular endothelial cells have been made using histological means 
in post-vitrectomy membranes
33-35
, no such assessment has been made when the cells 
are cultivated ex vivo under adherent conditions. 
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Figure 3. Clinical symptoms and pathomechanism of proliferative diabetic 
retinopathy (PDR) 
 
A. Patients with PDR suffer from visual field defects (the difference of visual 
perception is shown between normal subject (left) and patient having DR (right), B. 
Funduscopic,  fluorescein-angiography and OCT images of a patient suffering from 
PDR, recruited in the study. The same cotton wool spots, exudates, neovascularizations 
and hemorrhages are shown in C.  
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3. AIMS OF THE STUDY 
 
1. To determine and compare the gene expression pattern of ex vivo cultured 
human LESCs and differentiated CECs to identify possible new putative LESC 
markers.  
 
2. To discover new biological function or signaling-related pathways with custom 
made gene expression selection focusing on stemness and proliferation-, 
epithelial differentiation-, tissue development and growth-, immunological and 
angiogenic factors-related genes, based upon the differences found between 
LESCs and CECs. 
 
3. To compare the expression of mesenchymal stem cell (MSC)-related surface 
markers to the results obtained from the gene expression array of ex vivo 
cultured LESCs and CECs. 
 
4. To identify angiogenesis related signaling pathways and networks related to the 
IL-6 and IL-8 gene expression and protein secretion of LESCs. 
 
5. To isolate and cultivate cells from fvERMs (collected from patients with DR) 
and investigate their phenotype using cell surface markers for hematological-, 
endothelial-, MSCs- and cell adhesion molecules (CAMs) to determine the 
possible origin of these cells. 
 
6. To compare the phenotype of fvERM outgrowing cells to non-DR primary 
human retinal pigment epithelial (hRPE) cells. 
 
7. To investigate the angiogenic potential of the fvERM outgrowing cells under 
presence or absence of pro-inflammatory factor TNFα using high-throughput 
screening by angiogenic protein array. 
 
8. To measure the intracellular calcium dynamics in fvERM outgrowing cells in 
response to mechano-stimulation to prove the viability and functionality of these 
cells and to mimic the tractional forces appearing due to presence of fvERMs in 
PDR.  
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4. MATERIALS AND METHODS 
 
4.1. Tissue collection  
All tissue collection complied with the Guidelines of the Helsinki Declaration (1964) 
and was approved by the National Medical Ethics Committee of Hungary 
(14415/2013/EKU – 183/2013 and DEOEC RKEB/IKEB 3094/2010) and the National 
Medical Ethics Committee of the Republic of Slovenia. Limbal tissue and CEC 
collection was done within 12 hours of biologic death from cadavers and followed the 
EU Member States' Directive 2004/23/EC on presumed consent practice for tissue 
collection. Biologic death was always confirmed by a clinical team at the particular 
Clinic of death (mostly Internal Medicine) which was then followed by delivery to the 
Pathology Mortar. All relevant data pertaining to the status of the patient before death 
were checked before tissue collection.  
FvERMs were obtained from patients (Mean Age: 62.7+9.0 years) undergoing 
vitrectomy due to intravitreal hemorrhage in PDR (Table 1 shows the data for each 
patient). 
 Donor 1 Donor 2 Donor 3 
Age (years) 54 72 62 
Gender male female male 
Type of diabetes 1 2 2 
Duration of diabetes (years) 29 33 4 
Insulin therapy yes yes yes 
BMI 28.1 31.6 35.1 
Arterial hypertension yes yes yes 
Hyperlipidemia yes yes yes 
 
Table 1. Data of patients with proliferative diabetic retinopathy (PDR) 
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4.1.1. Isolation of LESCs and CECs 
Following enucleation, the bulbus was washed with 5% povidone iodine (Betadine; 
Egis Pharmaceuticals PLC, Budapest Hungary), then the conjunctiva was incised and 
separated from the limbal junction; consequently, a 2 x 1 mm rectangular-shaped limbal 
graft was dissected away and towards the cornea. The depth of the graft was kept 
superficial or within the epithelial layer. Multiple grafts were collected from a single 
eye and tested for growth potential. The graft dissection was performed using a lamellar 
knife placed tangential to the surface being cut. LESCs were cultured in a high-glucose 
Dulbecco-modified Eagle’s medium (DMEM-HG, Sigma-Aldrich, Budapest, Hungary) 
supplemented with 20% human AB serum, 200 mM/mL L-glutamine, 10,000 U/mL 
penicillin- 10 mg/mL streptomycin (all from Sigma-Aldrich) at 37
o
C, 5% CO2, the 
medium being changed every alternate day. The growth of the cells was monitored 
under phase contrast microscope regularly. Only grafts which had cell outgrowth within 
24 hours were processed further to decrease the chance of fibroblast contamination. 
Differentiated CECs were scraped from the central part of the cornea of cadavers and 
were used as a positive control. 
4.1.2. Isolation of fvERM outgrowing cells and hRPEs 
Immediately after the isolation, fvERMs were transported and cultivated ex vivo under 
adherent conditions in L-glutamin containing DMEM:F12 (Sigma-Aldrich, Ljubljana, 
Slovenia) supplemented with 10% fetal calf serum (FCS), antibiotics and antimycotics 
(PAA Laboratories GmbH, Pasching, Austria) and kept until reaching confluence. For 
control experiments, hRPE cells were used. The cells were isolated from cadavers and 
cultivated ex vivo (protocol modified from Thumann et al.
36
). The number of viable 
cells was determined with trypan blue exclusion assay after detachment with trypsin for 
further experiments. 
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4.2. Surface protein expression analysis by flow cytometry 
The phenotype of the isolated cells was determined by multicolor flow cytometry using 
FITC-, PE- and APC- conjugated antibodies against selected surface proteins (details 
are shown in Table 2). In the case of LESCs and CECs, the antibodies against MSC-
related markers, such as CD29/Integrin β1, CD44/HCAM, CD45, CD54/ICAM1, 
CD73, CD90/Thy-1, CD117/c-kit and CD146/MCAM were used in a concentration 
specified in the manufacturers’ protocol (all antibodies were obtained from Biolegend, 
San Diego, CA, USA). For the fvERM outgrowing cells and hRPEs, antibodies against 
CD11a/LFA-1, CD14, CD18/Integrin β2, CD29/Integrin β1, CD34, CD44/HCAM, 
CD49a, CD49d, CD51/Integrin αV, CD54, CD73, CD90/Thy-1, CD338/ABCG2, 
CD106/VCAM-1, CD166/ALCAM, PDGFRβ, HLA-G (Biolegend); CD105 (BD 
Bioscience, San Jose, CA, USA), CD47, CXCR4, CD146/MCAM, HLA-DR, 
VEGFR2, CD45, CD117 and CD31 (obtained from R&D Systems, Minneapolis, MN, 
USA) were used with the matching isotype controls as well. Cells were washed with 
their growth medium and twice with Fluorescence-Activated Cell Sorting (FACS) 
buffer after harvesting with 0.025% trypsin-EDTA. Samples were labeled for 30 
minutes on ice, then washed again with FACS buffer and fixed in 1% 
paraformaldehyde (PFA)/Phosphate buffered saline (PBS) and analyzed within 1 day. 
Measurement of the samples was carried out with FACSCalibur flow cytometer (BD 
Biosciences Immunocytometry
 
Systems, San Jose, CA, USA) and the data were 
analyzed using FlowJo (TreeStar, Ashland, OR, USA) software. The results were 
expressed as means of positive cells (%)+SD in the case of LESCs and CECs and 
means of positive cells (%)+SEM in the case of hRPE and fvERM, respectively. 
Hierarchical clustering was performed by the R software
37
. 
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Antibody Corp. Cat. No. Clone Concentration 
CD11a (LFA-1) BioLegend 350604 TS2/4 25 µg/mL 
CD14 BioLegend 325606 HCD14 200 µg/mL 
CD18 (Integrin β2) BioLegend 302106 TS1/18 400 µg/mL 
CD29 (Integrin β1) BioLegend 303004 TS2/16 100 µg/mL 
CD31 (PECAM) R & D Systems FAB3567P 9G11 25 µg/mL 
CD34 BioLegend 343504 581 25 µg/mL 
CD44 (H-CAM, Hermes) BioLegend 338804 BJ18 50 µg/mL 
CD45 R & D Systems FAB1430A 2D1 10 µg/mL 
CD47 R & D Systems FAB4670A 472603 10 µg/mL 
CD49a (Integrin α1) BioLegend 328304 TS2/7 50 µg/mL 
CD49d (Integrin α4) BioLegend 304304 9F10 12.5 µg/mL 
CD51 (Integrin αV) BioLegend 327908 NKI-M9 100 µg/mL 
CD54 (ICAM-1) BioLegend 353108 HA58 100 µg/mL 
CD73 BioLegend 344004 AD2 100 µg/mL 
CD90 (Thy-1) BioLegend 328108 5E10 50 µg/mL 
CD105 BD Biosciences 561443 266 200 µg/mL 
CD106 (VCAM-1) BioLegend 305806 STA 6.25 µg/mL 
CD117 (c-kit) R & D Systems FAB332P 47233 50 µg/mL 
CD140b (PDGFRβ) BioLegend 323606 18A2 400 µg/mL 
CD146 (MCAM) R & D Systems FAB932A 128018 10 µg/mL 
CD166 (ALCAM) BioLegend 343904 3A6 50 µg/mL 
CD184 (CXCR4) R & D Systems FAB173A 44717 25 µg/mL 
CD338 (ABCG2) BioLegend 332020 5D3 25 µg/mL 
HLA-DR R & D Systems FAB4869F L203 25 µg/mL 
HLA-G BioLegend 335910 87G 100 µg/mL 
VEGFR2 R & D Systems FAB357P 89106 50 µg/mL 
Table 2. Details of the fluorochrome-conjugated antibodies used in FACS 
 
4.3.1. Microarray and Data Analysis 
Total RNA from each analyzed sample was extracted by miRNeasy Mini Kit 
(QIAGEN, QIAGEN Inc.,Valencia, CA, USA) and quantiﬁed with NanoDrop (Thermo 
Fisher Scientific, Wilmington, DE, USA). RNA integrity was confirmed with 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). For microarray-
based gene expression profile analysis Affymetrix GeneChip Human Gene 1.0 ST 
Arrays (Affymetrix, Santa Clara, CA, USA) were used. The array contained 28,869 
gene transcripts. For the whole genome gene expression analysis 150 ng of total RNA 
was subjected to Ambion WT Expression Kit (Ambion, Life Technologies, Carlsbad, 
CA, USA) and GeneChip WT Terminal Labeling Kit (Affymetrix) according to the 
manufacturers’ protocols. After washing, the arrays were stained using the FS-450 
fluidics station (Affymetrix) and signal intensities were detected by Hewlett Packard 
Gene Array Scanner 3000 7G (Hewlett Packard, Palo Alto, CA, USA). The scanned 
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images were processed using GeneChip Command Console Software (AGCC) 
(Affymetrix) and the CEL files were imported into Partek Genomics Suite software 
(Partek, Inc. MO, USA). Robust microarray analysis (RMA) was applied for 
normalization. Gene transcripts with a maximal signal values less than 32 across all 
arrays were removed to filter for low and non-expressed genes, reducing the number of 
gene transcripts to 23,190. Differentially expressed genes between groups were 
identified using one-way ANOVA analysis in Partek Genomics Suite Software. 
Clustering analysis was made using the same name module in a Partek Genomics Suite 
Software. 
4.3.2. Pathway analysis 
To identify the relationships between selected genes, the Ingenuity Pathway Analysis 
(IPA, Ingenuity Systems, Redwood City, CA) was used. Excel datasheets containing 
gene IDs with the assigned gene expression values were uploaded into the program. 
The Ingenuity Pathways Knowledge Base (IPKB) provided all known functions and 
interactions which were published in the literature. ANOVA was used to calculate a p-
value to determine the probability that each biologic function or canonical pathway 
assigned to the data set was due to chance alone. For the representation of the 
relationships between the genes, the ‘Pathway Designer’ tool of the IPA software was 
used. 
4.4. Transmission electron microscopy 
Human corneal tissue procurement and use were conducted in accordance with local 
regulations and approved by the Research Ethics Committee of King Saud University. 
Unless specified otherwise, reagents were obtained from TAAB Laboratories 
Equipment Ltd. (Aldermaston, UK). Pieces of LESCs grown on lens capsules were 
ﬁxed in freshly prepared 4% paraformaldehyde in 0.1 M phosphate for 2hrs at 4°C. 
Tissues were processed at low temperatures and were embedded in LR White resin 
(Sigma-Aldrich) at −20°C for 48hrs under ultraviolet light. Ultrathin sections were 
collected on 200 mesh formvar-coated carbon nickel grids and examined in a Jeol 1400 
transmission electron microscope (Jeol Ltd, Tokyo, Japan). 
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4.5.1. Treatment and supernatant collection of fvERM outgrowing cells 
The expanded fvERM cells were plated onto 6 well plates at a density of 2x10
5
 cells per 
well in triplicates. After 24hrs, the medium was changed and the cells were treated with 
100ng/mL recombinant human TNFα (Preprotech, Rocky Hill, NJ, USA) for additional 
24hrs. The cells were then collected for analysis of the expression of cell surface 
markers and their supernatants collected and centrifuged at 1400rpm for 10 minutes. 
The centrifuged supernatants were then pooled into one stock pre-treated by 0.025N 
hydrochloric acid for 15 minutes at room temperature. The secreted factors were 
consequently analyzed by Human Angiogenesis Array (Proteome Profiler, R&D 
Systems, Minneapolis, MN, USA) and ELISA. 
4.5.2. Supernatant collection from LESCs 
LESCs were seeded on 24-well plates at a 5x10
4
 cell/mL density. Cells were cultured 
for 9 to 13 days. At the end of the culturing period, the supernatants were harvested and 
centrifuged at 1400rpm for 10 minutes to eliminate cellular debris from the samples. 
All the samples were then kept at -20°C until measurement took place. 
4.6.1. Measurement of secreted cytokine concentrations by ELISA 
BD OptEIA ELISA (BD Pharmingen, San Diego, CA, USA) assay kits were used 
following the supplier's instructions to measure the concentration of secreted IL-6 and 
IL-8 cytokines. Each experiment was performed at least three times and each sample 
was tested in triplicates. Statistically significant differences were determined by the 
paired Student’s t-test. 
4.6.2. Measurement of secreted angiogenesis related cytokines by Angiogenesis 
Protein array 
The Proteome Profiler Human Angiogenesis Array Kit (R&D Systems) provides a 
platform for detection of 55 different angiogenesis related cytokine in one raw. 
Measurements were carried out according to the manufacturer’s protocol. Briefly, the 
membranes were blocked with the manufacturers blocking solution, while 300 μl pre-
prepared supernatant used in the analysis was added to 200 μl Array Buffer 4 and 1ml 
Array Buffer 5, then the mixture was incubated with 15 µL reconstituted Detection 
Antibody Cocktail for additional 1hr. After the incubation, the mixture solution – 
containing the sample and the detection antibodies, were added to the membranes and 
incubated overnight at 4°C. After four washing steps, the membranes were incubated 
for 30 minutes with streptavidin-HRP solution, then the antibody-antigen reaction was 
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visualized with a chemiluminescent reaction. The membranes were exposed to X-ray 
films and developed with KODAK Medical X-Ray Processor 101. Data analysis was 
performed according to the manufacturer’s recommendation with ImageJ software. 
4.7. Calcium dynamics in the fvERM outgrowing cells 
The cultured fvERM outgrowing cells were loaded with acetoxymethyl (AM) ester of 
Fura-2 (Fura-2 AM; Invitrogen – Molecular Probes, Carlsbad, CA, USA), a free 
cytosolic calcium (Ca
2+
) sensitive dye, which was dissolved in DMSO and suspended 
in 1.5 mL of culture medium (final working concentration: 8 µM). The Fura-2 AM 
loading was carried out at 37
o
C, 5% CO2 for 40 minutes. After loading, the cultures 
were washed twice for 7 minutes with 3 mL of the physiological saline with (in mM): 
NaCl (131.8), KCl (5), MgCl2 (2), NaH2PO4 (0.5), NaHCO3 (2), CaCl2 (1.8), HEPES 
(10), glucose (10)), pH 7.24. The Petri dish was then mounted onto inverted 
microscope, Zeiss Axiovert S 100 (Carl Zeiss, AG, Oberkochen, Germany). To test 
responses to mechanical stimuli, the mechano-stimulation with a tip of a glass 
micropipette mounted on a MP-285 micromanipulator (Sutter, Novato, CA, USA) was 
used. Image acquisition was done with the 12-bit cooled CCD camera SensiCam (PCO 
Imaging AG, Kelheim, Germany). The software used for the acquisition was WinFluor 
(written by J. Dempster, University of Strathclyde, Glasgow, UK). Microscope 
objectives used were: 10x/ 0.30 Plan-NeoFluar and 63x⁄1.25 oil Plan-NeoFluar (Zeiss). 
The light source used was XBO-75W (Zeiss) Xe arc lamp. The excitation filters used, 
mounted on a Lambda LS-10 filter wheel (Sutter Instruments Co.) were 360 and 380 
nm (Chroma). Excitation with the 360 nm filter (close to the Fura-2 isosbestic point) 
allowed observation of the cells’ morphology and of the changes in the concentration of 
the dye, irrespective of changes in free cytosolic Ca
2+
 concentrations ([Ca
2+
]i), while 
the 360⁄380 nm ratio allowed visualization of the [Ca2+]i changes in the cytoplasm. 
Image acquisition, timing and filterwheel operation were all controlled by WinFluor 
software via a PCI6229 interface card (National Instruments, Austin, TX, USA). 
Individual image frames were acquired every 500 ms resulting in frame cycles being 1 
second long (two wavelengths).  
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4.8. Statistical analysis 
Each experiment was performed at least three times and each sample was tested in 
triplicates. Statistica 7.0 software (StatSoft Inc., USA) was used for the statistical 
analyses. Statistically significant difference between the two groups (fvERM cells vs. 
primary hRPE) was determined with paired Student’s t-test and a value of p<0.05 was 
considered significant. Data are expressed as mean+SD or SEM. 
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5. RESULTS 
 
5.1. Gene expression profiling of LESCs and CECs 
Comparing the transcriptional profiles of LESCs to differentiated CECs and based upon 
the intensity profiles of the log2 transformed signal values of the 28,869 transcripts, 955 
and 875 transcripts were found to have a more than 2 fold change (FC) increase and 
decrease in expression between the two cell types, respectively (n = 3, p<0.01). Based 
on the transcription data, the affected canonical pathways and biological functions were 
calculated, as well as top up- or down- regulated genes were identified with the IPA 
software. The top canonical pathways included genes involved in hepatic fibrosis, 
angiogenesis inhibition by thrombospondin 1 (TSP-1), retinoic acid receptor (RAR) 
activation, antigen presentation and axonal guidance signaling. Some of the signaling 
pathways were also related to diseases or toxicological pathways such as induction of 
reactive metabolites, renal ischemia and renal proliferation (Table 3).  
 
 Ingenuity Canonical Pathways -Log(B-H-P-
value) 
Ratio 
Top Canonical 
Pathways 
Hepatic Fibrosis/Hepatic Stellate 
Cell Activation 
8.36E-05 32/142 (0.225) 
Inhibition of Angiogenesis by TSP1 2.22E-04 12/34 (0.353) 
RAR Activation 5.01E-04 35/179 (0.196) 
Antigen Presentation Pathway 1.25E-03 11/40 (0.275) 
Axonal Guidance Signaling  1.31E-03 65/432 (0.15) 
Top Tox 
(toxicological) 
Pathways 
Hepatic Fibrosis  4.25E-06 27/93 (0.29) 
Glutathione Depletion - CYP 
Induction and Reactive Metabolites 
6.6E-05 
 
7/12 (0.583) 
Liver Proliferation  1.5E-04 39/189 (0.206) 
Persistent Renal Ischemia-
Reperfusion Injury (Mouse) 
4.41E-04 10/30 (0.333) 
Increases Renal Proliferation 4.54E-04 24/101 (0.238) 
 
Table 3. The most significantly affected canonical pathways found in LESCs 
IPA was used to calculate the canonical pathways from the gene expression profile of 
LESCs. 
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With further deep-analysis, more biological functions and diseases from the 
significantly changed expression levels of groups of genes were determined. 733 
molecules were found to be involved in cancer development, 344 in reproductive 
system diseases, 282 in dermatological diseases, 402 in gastrointestinal diseases and 
257 in endocrine system related disorders. Within the cellular functions’ group of 
genes, 567 were involved in cellular growth and proliferation, 552 in cellular 
development, 520 in cell death, 381 in cellular movement and 290 in cell-to-cell 
signaling. In system development, the IPA software found 371 genes involved in 
organogenesis and 350 in tissue development. High number of genes belonged to the 
cardiovascular development (271) and tumor morphogenesis (140) group. Only a small 
number of molecules related to visual system development and function (98) could be 
detected (Table 4). Furthermore, only 42 genes could be identified as related to clinical 
chemistry and hematology, 142 genes to be involved in cardiotoxicity, 205 in 
hepatotoxicity and 195 in nephrotoxicity, respectively (Table 4).  
5.2. Customized gene array data – upstream regulators in LESCs 
Groups from the significantly and differentially expressed upstream regulators in 
LESCs were generated in particular, those which were extensively related to 
physiological maintenance of the cells. 257 genes collected and divided into subgroups 
of interest such as stemness and proliferation, differentiation, cytokines and growth 
factors, angiogenesis and cell adhesion. Although there were significant inter-donor 
differences, the heatmap and the functional clustering of the genes demonstrated a clear 
distinction between the LESCs and the control differentiated CECs. The genes that 
were mostly affected were involved in ion-, nucleotide- or protein binding, protein 
secretion as well as receptor or enzyme activities (Figure 4). Most of the upregulated 
genes were involved in ECM re-organization or ECM-to-cell connection such as FN1 
(Fibronectin 1 with 74.934 fold change), MMP9 (type IV collagenase with 14.243 FC), 
MMP1 (interstitial collagenase, 13.875 FC), ICAM1 (Intercellular adhesion molecule 1, 
13.681 FC) and ITGA5 (fibronectin receptor with 13.455 FC respectively). Cytokines 
and growth hormones were also included in the selection (Table 5). 
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Function Name p value Molecules 
Diseases and 
Disorders 
Cancer 5.96E-27-1.23E-03 733 
Reproductive System Disease 1.61E-16-1.19E-03 344 
Dermatological Diseases and 
Conditions 
3.42E-16-1.15E-03 282 
 
Gastrointestinal Disease 4.31E-13-8.26E-04 402 
Endocrine System Disorders 2.65E-10-7.46E-04 257 
Molecular and 
Cellular 
Functions 
Cellular Movement 5.90E-18-1.43E-03 381 
Cellular Growth and 
Proliferation 
1.31E-10-1.12E-03 567 
Cellular Development 3.26E-09-1.07E-03 552 
Cell-To-Cell Signaling and 
Interaction 
8.23E-09-1.48E-03 290 
Cell Death and Survival 1.04E-08-1.48E-03 520 
Physiological 
System 
Development 
and Function 
Cardiovascular System 
Development and Function 
9.52E-10-1.23E-03 271 
Tumor Morphology 6.48E-09-9.47E-04 140 
Organismal Development 9.59E-09-1.48E-03 371 
Visual System Development and 
Function 
1.34E-07-1.48E-03 98 
Tissue Development 2.59E-07-1.48E-03 350 
Clinical 
Chemistry and 
Hematology 
Decreased Levels of Albumin 1.63E-03-3.94E-01 6 
Increased Levels of Alkaline 
Phosphatase 
2.79E-03-1.18E-01 16 
Increased Levels of Creatinine 8.01E-03-8.01E-03 8 
Increased Levels of Potassium 1.48E-02-5.41E-01 7 
Increased Levels of Albumin 1.09E-01-2.21E-01 5 
Cardiotoxicity Cardiac Stenosis 6.92E-04-3.13E-01 15 
Congenital Heart Anomaly 3.64E-03-5.28E-01 23 
Cardiac Arteriopathy 4.20E-03-6.33E-01 42 
Pulmonary Hypertension 5.95E-03-1.18E-01 11 
Cardiac Hypertrophy 8.04E-03-1.00E00 51 
Hepatotoxicity Liver Proliferation 2.37E-04-3.13E-01 39 
Liver Cholestasis 6.93E-04-5.84E-01 22 
Liver Cirrhosis 7.33E-04-2.21E-01 31 
Liver Damage 8.26E-04-2.21E-01 33 
Liver 
Hyperplasia/Hyperproliferation 
8.39E-03-5.03E-01 80 
Nephrotoxicity Renal Proliferation 6.16E-06-2.21E-01 38 
Renal Damage 7.17E-04-5.03E-01 37 
Renal Tubule Injury 7.17E-04-2.21E-01 24 
Renal Necrosis/Cell Death 1.84E-03-1.00E00 52 
Renal Inflammation 8.70E-03-1.00E00 34 
Table 4. Top biological and toxicological functions found in LESCs 
Biological functions based upon the most affected pathways in LESCs as determined by 
the IPA software.  
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Figure 4. Heatmap of the differentially expressed genes in LESCs compared to 
CECs 
A. Heatmap of the transcripts and functional clustering of 257 genes expressed in a 
significantly different way in LESCs compared to CECs, and related to stemness, 
epithelial differentiation, tissue organization and angiogenesis. Red and blue colors 
indicate high and low expression, respectively. The cluster analysis and dendrogram 
show the difference between the two cell types, B. Distribution of the 257 significantly 
differentially expressed genes by molecule type as defined by the IPA software. 
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Symbol Entrez gene name FC z-score p-value  Molecule  
Fold Change up-regulated 
FN1  Fibronectin 1 74.934 2.979 8.37E-05 enzyme 
CCNA1 Cyclin A1 27.199  3.42E-02 other 
IL1B Interleukin 1, beta 24.948 4.924 8.09E-15 cytokine 
INHBA Inhibin, beta A 21.815 1.352 2.27E-04 growth factor 
SERPINE1 Serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 1 
18.854 -0.927 1.40E-02 other 
GDF15 Growth differentiation factor 
15 
16.924 1.999 2.63E-02 growth factor 
PTHLH Parathyroid hormone-like 
hormone 
16.2 1.972 8.72E-03 other 
OSMR Oncostatin M receptor 15.366 1.982 1.83E-02 TM receptor 
CXCL10 Chemokine (C-X-C motif) 
ligand 10 
15.171 0.911 2.31E-02 cytokine 
MMP9 Matrix metallopeptidase 9 
(gelatinase B, 92kDa type IV 
collagenase) 
14.243 0.689 1.72E-02 peptidase 
IL1R1 interleukin 1 receptor, type I 13.972 2.603 5.76E-03 TM receptor 
MMP1  Matrix metallopeptidase 1 
(interstitial collagenase) 
13.875 1.188 4.01E-03 peptidase 
ICAM1 Intercellular adhesion 
molecule 1 
13.681 2.961 1.36E-03 TM receptor 
ITGA5 Integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide) 
13.455 2.411 1.46E-02 other 
SH3KBP1 SH3-domain kinase binding 
protein 1 
12.752  4.98E-02 other 
AKT3 V-akt murine thymoma viral 
oncogene homolog 3 (protein 
kinase B, gamma) 
11.843  4.76E-02 kinase 
LOXL2 Lysyl oxidase-like 2 11.734 1.992 1.88E-03 enzyme 
CEACAM5 Carcinoembryonic antigen-
related cell adhesion 
molecule 5 
10.588  1.23E-02 other 
SLPI Secretory leukocyte peptidase 
inhibitor 
8.53 -2.433 1.06E-02 other 
PDZK1IP1 PDZK1 interacting protein 1 8.485  1.23E-02 other 
 
Table 5. Top 20 up-regulated genes in LESCs 
Top 20 up-regulated genes determined by the IPA software. The genes shown code for 
cytokines, enzymes and receptors, and are involved in cell-migration, ECM re-
organization and immune responses.  
(FC: Fold change, p-value: p- value of overlap, TM receptor: transmembrane receptor)   
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Symbol Entrez gene name FC z-score p-value  Molecule  
Fold Change down-regulated 
CRTAC1 Cartilage acidic protein 1 -72.277    
LPA Lipoprotein, Lp(a) -11,623  4.98E-02 Other 
ETV1 Ets variant gene 1 -7,444 1.969 1.83E-02 transcription 
regulator 
EDNRB Endothelin receptor type B -7,25  3.38E-02 G-protein 
coupled 
receptor 
BMP7 Bone morphogenetic protein 7 -6,436 0.733 1.17E-04 growth factor 
NREP Neuronal regeneration related 
protein 
-5,823 -0.248 3.81E-03 Other 
CFTR Cystic fibrosis transmembrane 
conductance regulator (ATP-
binding cassette sub-family C, 
member 7) 
-5,766 -1.993 1.49E-01 ion channel 
DCN Decorin -5,066 0.172 6.04E-07 Other 
RORA RAR-related orphan receptor 
alpha 
-4,781 -0.439 2.61E-03 ligand-
dependent 
nuclear 
receptor 
LEF1 Lymphoid enhancer binding 
factor 1 
-4,441 -0.306 2.01E-02 transcription 
regulator 
BDKRB1 Bradykinin receptor B1 -4,1 -2.000 6.89E-04 G-protein 
coupled 
receptor 
GJA1 Gap junction protein, alpha 1 -3,94 -1.480 5.54E-04 transporter 
FAM3B Family with sequence 
similarity 3, member B 
-3,9  3.20E-08 cytokine 
P2RX7 Purinergic receptor P2X, 
ligand-gated ion channel, 7 
-3,885  1.15E-02 ion channel 
KAT2B K(lysine) acetyltransferase 2B -3,829 1.963 8.27E-02 transcription 
regulator 
ODC1 Ornithine decarboxylase, 
structural 1 
-3,63  4.98E-02 Enzyme 
EPHX2 Epoxide hydrolase 2, 
cytoplasm 
-3,469  3.42E-02 Enzyme 
MAT1A Methionine 
adenosyltransferase I, alpha 
-3,386 -0.215 1.82E-02 Enzyme 
CTSL2 Cathepsin L2 -3,385  4.98E-02 peptidase 
DUSP1 Dual specificity phosphatase 1 -3,358 -1.881 6.12E-02 phosphatase 
NOV Nephroblastoma overexpressed -3,149 0.555 1.94E-02 growth factor 
Table 6. Top 20 Down-regulated genes in LESCs 
Top 20 down-regulated genes determined by the IPA software. The genes shown code 
for cytokines, enzymes and receptors, and are involved in cell-migration, ECM re-
organization and immune responses.  
(FC: Fold change, p-value: p- value of overlap, TM receptor: transmembrane receptor) 
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5.3. Customized gene networks – upstream regulators in LESCs 
5.3.1. Stemness and proliferation 
122 upstream regulators were found to be related to stemness and proliferation in 
LESCs, in particular, to be related to MSCs. The heatmap of the significantly expressed 
genes within this group, besides the cluster analysis, showed a clear difference between 
the LESCs and the CECs (Figure 5A). These differential genes coded for 
transcriptional factors, surface molecules, cytokines and growth factors, all playing a 
key role in the maintenance of multipotency and proliferation capacity of stem cells 
(Figure 5B). Up- and down- regulation was also found in 66 and 56 genes, 
respectively, and within the custom selected gene cluster. The 10 most highly expressed 
upstream regulators were: CCNA1 (27.199 fold), IL1B (24.948), GDF15 (16.924), 
ICAM1 (13.681), TGFB (16.745), SOX9 (4.859 fold), VIM (4.368), NT5E (4.009), 
TGFBR2 (3.772) and BMP6 (3.494), while the 10 most down-regulated regulators 
were: BMP7 (-6.436 fold), LEF1 (-4.441), GJA1 (-3.94), KAT2B (-3.829), KLF4 (-
3.041), EGF (-2.563), FOXN1 (-2.11), SOX6 (-1.984), GDF9 (-1.865) and HSPA9 (-
1.838). The expression pattern of the selected genes confirmed that the LESCs have a 
higher proliferation potential and stemness-related gene expression than differentiated 
CECs. The SRY related HMG-box family members SOX9 and SOX6, both involved in 
chondrogenesis and proliferation, were down-regulated in the LESCs. 
5.3.2. Differentiation 
LESCs play a key role in the re-epithelialization of the cornea, so 42 genes were 
analyzed that are related to terminal and epithelial differentiation. Based on the 
transcription level of the selected genes, LESCs segregated well from the differentiated 
CECs (Figure 6A). This group of upstream regulators consisted of growth factors, 
cytokines, adhesion molecules, transcription regulators and enzymes (Figure 6B). 
Transcriptional regulators such as FOXA1 and PMEL were up-regulated in contrast to 
FOXG1 (-1.165), FOXD3 (-1.1), MYOD1 and OSGIN1 (-1.109) which were among the 
downregulated genes (Figure 6C). The pericellular matrix proteoglycan decorin coding 
gene DCN (-5.066) was found to be down-regulated in LESCs. Within the collection of 
cytokines and growth factors which play a role in epithelial differentiation, IL1B 
(24.948), INHBA (21.815), IL1A (7.853), TGFB1 (6.745), EREG (3.836), BMP6 
(3.494) and DKK1 (2.88) were up-regulated, while BMP7 (-6.436 fold), FGF1 (-2.96), 
FGF7 (-1.473), IL18 (-1.152) and IGF2 (-1.126) were down-regulated (Figure 6D).  
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5.3.3. Cytokines and growth factors 
Cytokines and growth factors have an important function in differentiation, maturation 
of cells, cell-cell communication, as well as controlling immunogenicity. Their 
expression level was different in LESCs compared to CECs (Figure 7A). The most up-
regulated gene in this group was IL1B (24.948 FC), followed by CXCL10 (15.171), 
IL1A (7.853), IL8 (5.849), EDN1 (5.504), IFNE (4.601), IL6 (2.57), SPP1 (2.077) and 
CCL5 (1.973). These genes code for pro-inflammatory cytokines, while other cytokine 
family genes which have similar pro-inflammatory properties, such as IL17 (-1.129), 
IL-1 superfamily members IL18 (-1.152) and IL36RN (-1.059), were down-regulated. 
Human EDA (-1.113) which belongs to the TNF family was within the most down-
regulated genes, while the top down-regulated gene was FAM3B (-3.900) (Figure 7B). 
Growth factors are important in the maintenance of stemness, pluripotency of stem- or 
progenitor cells, playing a key role in differentiation, tissue and organ development. 
The detected genes in this group were related to epidermal growth factor (EGF) and 
TGF beta (TGFβ) superfamily. In particular, INHBA (21.815 fold), GDF15 (16.924), 
TGFB1 (6.745) and BMP6 (3.494) – all members of the TGFβ family, were among the 
most up-regulated genes. Other genes such as epiregulin - EREG (3.836), amphiregulin 
- AREG (4.047) and connective tissue growth factor CTGF (6.513) were in the top up-
regulated genes as well, while other TGFβ superfamily members such as BMP7 (-
6.436) and GDF9 (-1.865), acidic fibroblast growth factor, FGF1 (-2.96) and FGF7 (-
1.473), were all down-regulated. Similarly, NOV-like CTGF- member of the CCN 
protein family: nephroblastoma overexpressed/NOV (-3.149) and the EGF (-2.563) 
gene expression responsible for regulation of cell division and proliferation were both 
down-regulated (Figure 7C). 
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Figure 5. Upstream regulators as determinants for stemness and multipotency 
A. Genes involved in the maintenance of stemness, cell cycle and multipotency-related 
transcriptional factors, and B. growth factors, cytokines and corresponding receptors. 
Genes characteristic for MSCs are grouped and highlighted as well. 
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Figure 6. Expression of 42 epithelial- and terminal differentiation-related genes 
A. Expression of transcriptional factors, transmembrane receptors, enzymes and 
adhesion molecules involved in epithelial- or terminal differentiation. B. Subgroups of 
cytokines- and growth factor-coding genes involved in epithelial differentiation of stem 
cells, C. Distribution of the selected 42 upstream regulators by molecule type, such as, 
C. transcriptional regulators and D. growth factors and cytokines. 
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Figure 7. Transcriptional pattern of the cytokines- and growth factors- coding 
genes 
A. In comparison to CECs, the LESCs expressed 37 cytokines- and 40 growth factors- 
coding genes in a significantly different manner, B. Selection of significantly and 
differentially expressed genes of cytokines, C. expression of differentiation and growth 
factors genes.  
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5.3.4. Cell adhesion 
To further distinct the multipotent LESCs within the heterogeneous population of 
epithelial cells, surface markers including ECM-cell and cell-cell adhesion, as well as 
cell migration genes were used as putative markers. The upstream regulators of 54 
genes coding for molecules involved in cell adhesion were analyzed (Figure 8A,E). In 
the first subgroup, highly expressed transcriptional factors and transmembrane 
receptors were collected. This group contained MAP2K (12.088), AKT3 (11.843), 
TGFBI (6.745), CTGF (6.513), SPP1 (2.077) and SRC (1.931) as up-, and AKT1 (-
1.026), ROCK2 (-1.076), PRKCA (-1.154), HRAS (-1.5), PRKCB (-1.583) and NOV (-
3.149) as down-regulated genes (Figure 8C). The next subgroup, included genes 
coding for integrins, cell adhesion molecules (CAMs), proteolytic enzymes and matrix 
metalloproteases (MMPs) – all involved in the ECM breakdown and tissue healing and 
remodeling (Figure 8D). Within this cluster, MMP9 (14.243), MMP1 (13.875), and 
MMP14 (1.836) were found to be the most up-regulated genes, while the other family 
member MMP3 was down-regulated (-1.105). Laminins, which encode important 
proteins of the basal membrane, were all up-regulated - LAMA3 (3.289), LAMC1 
(1.724) and LAMA1 (1.428), in the LESCs. Integrins, CAMs and tight junctions, which 
are very important in cell-cell adhesion and tissue organization were up-regulated - 
ICAM-1 (13.681), CAV1 (1.608) and CLDN7 (3.056), while GJA1 (-3.94) was down- 
regulated within this custom-made group. In particular, CDH1 (1.536), an important 
component of the desmosomal junction formation and stratified epithelium 
transformation was up-regulated; the desmosome formation between the LESCs grown 
on lens capsule could be demonstrated using transmission electron microscopy (Figure 
8B). Altogether, the expression of 11 integrin-coding genes was different between the 
LESCs and the differentiated CECs - 8 out of them were up-, while 3 were down- 
regulated.  
5.3.5. Angiogenesis 
The dataset was filtered for molecules which may have a role in pathological 
angiogenesis in the cornea. The heatmap of the detected 48 genes shows the differential 
expression profile of LESCs and CECs (Figure 9A). The molecule types coded by the 
angiogenesis-related genes could be divided into transcriptional factors, enzymes and 
cytokines including angiogenic growth factors as well (Figure 9B). The fibronectin 
(FN1) gene, which is important in new vessel sprout formation, had the highest up-
regulation (74.934), followed by SERPINE1 (18.854) and MMP9 (14.243). The 
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coagulation factor III (thromboplastin) gene F3 (7.054) was also highly expressed in 
the LESCs. The most down-regulated genes were PLG (-2.521), TIMP1 (-1.658), 
FOXO4 (-1.213), TGFBR1 (-1.179) (Figure 9C). Certain cytokines and growth factors 
which are also important in angiogenesis were up-regulated in the LESCs: ILB1 
(24.948), C-X-C motif chemokine 10, CXCL10 (15.171), TGFB1 (6.745) and VEGFA 
(2.742) (Figure 9D). In addition, IL-6 and IL-8, two very potent angiogenic cytokines, 
were also up-regulated in these cells: IL-6 (2.57) and IL-8 (5.849), similar to EDN1 
(5.504), EREG (3.836) and BMP2 (2.686). Only four of the angiogenic cytokines were 
down-regulated in the LESCs: acidic FGF - FGF1 (-2.96), IL17F (-1.129), TGFB2 (-
1.106) and KITLG (-1.015). 
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Figure 8. Differential changes in selected genes related to cell-cell junction, cell-to-
cell and cell-to-extracellular matrix (ECM) adhesion.  
A. Collection of significantly different expressions of transcriptional factors, kinases 
and transmembrane receptors related to cell-cell connection and adhesion, C and D. 
CAMs, integrins and ECM receptors determining the tissue origin of the LESCs, E. 
Molecule types of the selected 54 upstream regulator in the two groups of cells, B. 
TEM pictures from LESCs grown on lens capsule (LC) and showing cell-cell junctions 
among the cells (LC = Lens capsule, A = attachment between LC and cells; C1
,
, C2 and 
C3 = three cell-layers, L = translucent space, D = Desmosomes). 
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Figure 9. Expression of angiogenesis-related genes in LESCs 
A. MMPs, proteolytic enzymes and ECM proteins play a key role in the angiogenic 
processes, B. Cytokines and growth factors are important players during angiogenesis 
and endothelial cell activation as well as EPC/stem cell differentiation, C and D. Most 
of the angiogenic molecules belong to the shown molecule types. 
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5.4. IL-6 and IL-8 signaling pathway analysis by IPA  
 IL-6 and IL-8 are important cytokines not only in the inflammatory 
processes, but play a key role in maintaining stemness, differentiation and 
immunosuppression of stem cells, as well as epithelial differentiation and 
angiogenesis
38-41
. Their gene expressions were up-regulated in LESCs: IL-6 (2.570) and 
IL-8 (5.849), respectively. Using the IPA software analysis, the IL-6 signaling 
pathways were further confirmed of being present in the LESCs compared to CECs, 
together with some other well-known pathways described below (Figure 10A).  
Secretion of IL-6 depends on many stimulatory signals; hallmark pathway is the 
response of activated cells to pro-inflammatory stimuli, such as IL-1β- and TNFα-
mediated activation. This signaling is further mediated by the NFκB and JNK (JUN, C-
Fos) transcriptional factors and can lead to IL-6 and IL-8 release in parallel to collagen 
type I production (COL1A1), which is the major component of connective tissue. The 
second network affected is the autocrine or IL-6-mediated-IL-6-secretion through 
RAF1, MAP2K and ERK1/2. This process needs to be initiated by the IL-6 receptor 
(IL6R), however, the JAK-STAT pathway (STAT3) can also induce release of 
angiogenic factors such as VEGF and activation of SOX3. As shown before in our 
dataset, IL1B was highly up-regulated with a 24.948 fold change hand-in-hand with its 
receptor IL1R1 (13.972) and IL1A (7.853). Although a subunit of the receptor for IL-6 
coding gene was down-regulated - IL6R (-2.640), a member of the type I cytokine 
receptor family - oncostatin M receptor (OSMR), was found to be highly up-regulated 
(15.366) in the LESCs. In our dataset, SOCS3 was up-regulated (1.397), while SOCS1 
was down-regulated (-1.120). Four MAPKs were slightly up-regulated in the LESCs: 
MAP2K1 (2.088), MAPK1 (1.339), MAPK14 (1.011) and MAPK3 (1.163), while the 
members of the NFκB pathway were down-regulated: NFKB1 (-1.178) and NFKBIA (-
1.193). CXCL10 in presence of high amount of IL-6 has been shown to induce 
migration of trophoblasts through activation of the CXCR3 receptor
42
. Interestingly, 
CXCL10 was among the highest up-regulated genes (15.171) in the LESCs compared to 
the CECs (Figure 10B). 
 The pathways in which IL-8 participates are in general more complex than 
for other cytokines, due to its multipotent effect on the different cell types. IL-8 can act 
as chemotactic factor for neutrophils, can activate immune cells
43
, stem cells and has 
been also described as potent pro-angiogenic cytokine, especially in the eye (Figure 
11A)
44, 45
. The molecular background of such angiogenic processes has not been well 
described, but IL-8 seems to be an important activator of circulating EPCs with myeloid 
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origin. IL-8 can bind to G protein-coupled serpentine receptors such as CXCR1 and 
CXCR2 and beside immunological activation, it can induce rearrangement of 
cytoskeletal proteins, increase the expression of VCAM and ICAM1, and the migration 
as well as vessel formation of endothelial cells and stem cell-like EPCs, in parallel with 
increase in vascular permeability (Figure 11B). 
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Figure 10. Networks related to IL-6 signaling pathway as detected by the IPA 
software. 
The colored genes appear in the studied dataset: red color means up-, while green color 
means down-regulated. The grey colored genes did not fit the cut off level. A and B. 44 
upstream regulators of the IL-6 signaling pathway in LESCs when grouped upon 
biological functions of a molecule type. 
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Figure 11. Networks of IL-8 mediated signaling pathways generated by the IPA 
software  
A. IL-8 plays a key role in innate immunity, B. and as pro-angiogenic cytokine. The 
colored genes appear in the studied dataset: red color means up-, while green color 
means down-regulated. The grey colored genes did not fit the cut off level. 
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5.5. IL-6 and IL-8 secretion by LESCs  
The level of IL-6 and IL-8 cytokines in the LESC culture supernatants were measured 
by ELISA and were continuously high and correlated well with the gene expression 
data. At day 9, the level of IL-6 was 5885.24+685.6 pg/mL (Data are Mean+SEM), and 
at day 13 it was 6147.14+530.21 pg/mL, with no significant difference at both time 
points (p=0.778) (Figure 12). The same pattern could be observed in the IL-8 levels, 
6665.00+312.41 pg/mL could be detected at day 9 and 7429.52+352.43 pg/mL at day 
13, without significant difference between the two (p=0.14). 
 
 
 
 
 
 
Figure 12. Secreted IL-6 and IL-8 levels by LESCs 
The levels of secreted IL-6 and IL-8 as measured by ELISA in the supernatants of long 
term LESC cultures (N=21, p values were determined by Student’s t-test). 
 
5.6. Phenotype analysis of LESCs and CECs 
Genes coding MSC-related surface markers were measured at the protein level as well. 
Interestingly, no difference was found in the positivity for CD90 (8.75+19.56% in 
LESCs and 1.77+3.54% in CECs, respectively; p=0.4748, data shown are Mean+SD) 
and CD73 (89.86+6.15% in LECSs and 76.93+17.43% in CECs, respectively; 
p=0.2374). In the LESC cell cultures, more cells expressed the stem cell factor receptor 
CD117/c-kit (19.87+24.92%) compared to the CECs (0+0), however, this difference 
was not statistically significant (p=0.1491) due to a high inter-donor variance (Figure 
13A). CAMs and integrins showed more difference between the two cell types. At a 
protein level, CD146/MCAM was found not to be expressed on the surface of CECs 
(0+0%) compared to LESCs (82.40+14.60%, p=0.0002) and higher number of positive 
cells for ICAM1 in CECs (56.19+12.46%) than in LESCs (4.37+ 7.63%) (p=0.0001) 
could be observed. No difference could be found between LESCs and CECs in the 
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expression of CD29/Integrin β1 (97.01+1.87% and 78.28+15.84%, respectively), and 
CD44/HCAM (16.55+23.21% and 19.83+21.55%, respectively). The percentage of 
CD47 positive cells, which plays a role in cell viability and immune regulation, was 
significantly higher in LESCs (98.98+0.57%) compared to CECs (25.9+27.44%) 
(p=0.0039), showing higher viability and inhibition of phagocytosis in the LESCs 
(Figure 13A). The percentage of the positive cells for the selected surface proteins 
within the cell cultures showed different pattern in LESCs compared to CECs when 
using a cluster analysis (Figure 13B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Surface protein level analysis on LESCs and CECs by FACS.  
A. Positivity of the LECSs and CECs for CD73, CD90/Thy-1, CD117/c-kit, 
CD146/MCAM, CD29/Integrin β1, CD44/H-CAM, CD47 was determined by flow 
cytometry. CD45 was used as a negative control in these cells (Data shown are 
Mean+SD; p<0.05 *, p<0.01 **, p<0.001 ***; N=6 for the CECs, and N=5 for the 
LESCs), B. Cluster analysis showed a clear difference between the LESCs and the 
CECs. 
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5.7. Immunophenotyping of the fvERM outgrowing cells 
The fvERM outgrowing cells assumed an elongated, fibroblastoid-like morphology 
when cultivated under adherent conditions ex vivo (Figure 14A). The surface marker 
expression profile of the cultivated fvERM cells was compared to that of primary hRPE 
cells (Figure 14B (cluster analysis) and Table 7). The ex vivo cultured fvERM cells 
showed no purely common hematopoietic or monocyte phenotype. Similarly, these 
cells expressed no CD45, CD11a (LFA-1) and HLA-G, like the primary hRPE cells (an 
exception being the very low CD11a expression in one of the hRPE donors). Higher 
percentage of the primary hRPE cells were positive for CD14 (66.60+11.26%) 
compared to the fvERM cells (1.81+1.06%, p=0.005), while inversely, higher CD47 
expression was observed on the fvERM (97.95+0.44%) compared to the primary hRPE 
cells (88.04+5.48%) – the latter showing that the outgrowing fvERM cells were indeed 
viable cells. Both cell types had a low surface expression of HLA-DR (0.08+0.08% in 
fvERM cells vs. 1.00+1.00% in hRPE), while the percentage of CD117/c-kit 
(0.94+0.76% and 19.80+16.53%), CXCR4 (0.41+0.25% and 7.28+5.22%) and 
CD338/ABCG2 (0.80+0.08% and 17.63+15.09%) cells was, in general, lower in the 
fvERM compared to the primary hRPE, respectively. Only the expression of CD34 was 
more abundant in the fvERM cultures (21.81+15.78%) compared to the primary hRPE 
(2.34+1.17%), however, this difference was not statistically significant. Similarly, the 
expression of CD73, CD105 and PDGFRβ was not significantly different between the 
fvERM cells and the primary hRPEs, while a significant difference in the CD90 
expression was measured between the two cell types (68.19+0.46% in fvERM cells vs. 
91.16+6.66% in primary hRPE, p= 0.03). 
Among the cell adhesion molecules (CAMs) and integrins - all being important for 
maintaining the fate of the cells in their environment, significantly lower expression of 
CD18/Integrin β2 (p=0.01) and CD51/Integrin αV (p= 0.004) was found on fvERM 
cells compared to primary hRPE cells. The expression of CD29/integrin β1, 
CD49a/integrin α1, CD49d/ integrin α4, CD54/Intercellular adhesion molecule 1 
(ICAM-1), CD106/V-CAM 1, CD146/MCAM and CD166/ALCAM on fvERM cells 
were similar to those detected on primary hRPEs.  
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Figure 14. Morphology and immunophenotype of the fvERM outgrowing cells 
A. Morphology and B. hierarchical clustering based upon the expressed surface 
markers on fvERM outgrowing cells, in comparison to primary hRPE cells. (fvERM 
D1, 2 and 3 are fvERM Donor 1, 2 and 3 respectively; Data shown are representative of 
3 independent experiments on 3 different donor fvERM samples) 
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  fvERM cells Primary hRPE cells  
Hematopoietic 
 
Monocyte 
markers 
CD11a (LFA-1) 0.00 + 0.00 0.00 + 0.00  
CD14 1.81 + 1.06 66.60 + 11.26 ** 
CD34 21.81 + 15.78 2.34 + 1.17  
CD45 0.00 + 0.00 0.00 + 0.00  
CD47 97.95 + 0.44 88.04 + 5.48  
CD117/c-kit 0.94 + 0.76 19.80 + 16.53  
CXCR4 0.41 + 0.25 7.28 + 5.22  
HLA-DR 0.08 + 0.08 1.00 + 1.00  
HLA-G 0.00 + 0.00 0.00 + 0.00  
CD338 (ABCG2) 0.80 + 0.08 17.63 + 15.09  
MSC 
Fibroblast 
markers 
CD73 98.37 + 0.32 76.55 + 22.76  
CD90/Thy-1 68.19 + 0.46 91.16 + 6.66 * 
CD105/Endoglin 0.29 + 0.29 23.10 + 11.60  
PDGF Rβ 36.46 + 14.11 56.59 + 7.66  
CAMs 
Integrins 
CD18 (Integrin β2) 0.25 + 0.17 69.86 + 16.38 * 
CD29/Integrin β1 98.34 + 0.48 98.38 + 1.40  
CD31/PECAM 0.00 + 0.00 7.60 + 6.52  
CD44/H-CAM 96.78 + 1.06 89.03 + 6.71  
CD49a/Integrin α1 6.06 + 3.53 50.36 + 25.67  
CD49b/ Integrin α2 0.11 + 0.07 49.30 + 25.56  
CD51 Integrin αV 21.07 + 9.14 85.98 + 5.54 ** 
CD54/ICAM-1 32.65 + 5.45 52.47 + 10.83  
CD106/V-CAM 1 4.17 + 2.60 6.43 + 3.85  
CD146/MCAM 5.91 + 5.69 24.58 + 23.52  
CD166/ALCAM 95.70 + 1.64 95.28 + 4.47  
 
Table 7. Surface markers expression on fvERM outgrowing cells and primary 
hRPE cells  
The expression of different groups of surface markers was compared between fvERM 
outgrowing- and primary hRPE cells. The two cell types showed differential expression 
of CD14, CD18/Integrin β2, CD51/Integrin αV and CD90/Thy-1. (Data shown 
represent percentage of positive cells within the total cell culture and are representative 
of 3 independent experiments on 3 different donor fvERM samples, Mean+SD; p<0.05 
*, p<0.01 **) 
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5.8. Detection of angiogenic factors secreted by the fvERM outgrowing cells 
Altogether 55 angiogenesis-related markers were screened from the supernatants of the 
fvERM outgrowing cells under presence or absence of TNFα treatment. Unstimulated 
fvERM cells expressed high amount of serine protease inhibitor E1 (Serpin E1), also 
known as endothelial plasminogen activator inhibitor 1 (PAI-1; at pixel density 
28891+1096.02) and tissue inhibitor of metalloproteinase 1 (TIMP-1; at pixel density 
45238.5+1170.26) as shown in Figure 15. After 24 hours of pro-inflammatory 
stimulation by TNFα, both factors increased further in the supernatants of the treated 
compared to the control untreated cells (Serpine E1 with pixel density 87418.5+243.24 
and TIMP-1 with 113313+9050.26, respectively). More importantly, 11 secreted 
angiogenesis-related factors could be detected in the cell culture media of fvERM cells 
treated by TNFα that were otherwise absent in the untreated controls. Besides Serpine 
E1, the anti-angiogenic and tumorigenic pigment epithelium-derived factor (PEDF, also 
known as Serpin F1) was induced and secreted (at pixel density 20601.5+1045.10). 
Endothelin 1 (ET-1; at pixel density 11427+2065.46), a molecule that has been 
implicated in the development and progression of vascular disorders and usually 
secreted by endothelial cells upon stimulation by pro-inflammatory cytokines or 
hypoxia, could also be detected upon TNFα treatment (Figure 15). In addition, TNFα 
stimulation caused expression of 14 TNF-inducible proteins, among them being the 
pentraxin-related protein 3 (PTX3), which is a marker for rapid primary local activation 
of innate immunity and inflammation (at pixel density 51756+2533.56). Monocyte 
chemotactic protein-1 (MCP-1 or CCL2; at pixel density 15799.5+5861.92) and IL-8 
(also referred as CXCL8; at pixel density 94931+9130.87) were both released by the 
TNFα treated, but not the untreated fvERM outgrowing cells – these molecules play an 
important role as monocyte chemo-attractant proteins. High pixel density of 
thrombospondin 1 (TSP-1; 28239+2942.27) could also be measured in the proteome 
profiler array of the TNFα stimulated fvERM outgrowing cells, referring to its many 
angiogenic and anti-angiogenic functions that depend upon its binding factor 
alternatives. Endocrine-gland-derived vascular endothelial growth factor (EG-
VEGF)/prokineticin (PK), which is a new members of the angiogenic cytokine family, 
was also secreted by the TNFα stimulated cells, although in low amounts (at pixel 
density 3698+627.20), and it could not be detected in the control cell culture 
supernatants. Dipeptidyl peptidase-4 (DPPIV, also known as CD26), which plays a key 
role in the glucose metabolism, underwent induction upon TNFα treatment (at pixel 
density 15854.5+2201.93). In addition, two members of the insulin-like growth factor-
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binding proteins (IGFBPs) appeared upon the TNFα pro-inflammatory stimulus: 
IGFBP-2 (at pixel density 15965.5+222.03) and IGFBP-3 (at pixel density 
41872.5+2607.81). Matrix metallopeptidase 9 (MMP-9), which has many biological 
functions, among them being facilitation of angiogenesis upon inflammatory 
stimulation, also increased upon TNFα treatment (at pixel density 8989.5+134.35), 
while it was absent in the supernatants from the control fvERM outgrowing cells. 
 
 
Figure 15. Angiogenic factors secreted by the fvERM outgrowing cells.  
The fvERM cells were treated with 100ng/mL TNFα for 24 hours. Supernatants were 
collected and the cytokine levels were determined by a Human Angiogenesis Array 
Proteome Profiler. A. Map of the 55 angiogenesis-related proteins detected on the 
membranes. B. Panel of the secreted proteins of control and TNFα treated cells. 
(Mean+SD; p<0.05 *, p<0.01 **) 
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5.9. Surface marker expression of fvERM outgrowing cells upon TNFα treatment 
In correlation to the FACS surface immunophenotype of the fvERM outgrowing cells, 
TNFα treatment increased the percentage of CD54/ICAM-1 positive cells within the 
cell cultures and the amount of the surface protein as well (Figure 16A,B), but had no 
influence on the VEGFR2 or CXCR4 expression, indicating that these cells do not 
participate directly in the angiogenesis process through endothelial differentiation. 
 
 
 
Figure 16. Surface marker-analysis of the TNFα treated fvERM outgrowing cells 
A. Percentage of positive cells for the selected markers and their expression levels of 
the surface proteins as measured by flow cytometry. Not just the number of positive 
cells, but the protein level on the surface of the fvERM outgrowing cells increased in 
case of CD54 in response to recombinant TNFα treatment. B. Color-dotplots of 
untreated and treated cells. (Data shown are Mean+SD of 3 independent experiments on 
3 different donor fvERM samples, p<0.01 **) 
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5.10. Functionality and viability of the fvERM outgrowing cells 
The dynamics of [Ca2
+
]i upon mechanical stimulation reflects well upon the 
functionality and viability of the outgrowing fvERM outgrowing cells, and such 
mechanical tractional forces can be common in fvERMs in late stages of PDR
46
. 
Mechano-stimulation was induced by a glass micropipette applied to a single cell 
(Figure 17A), which caused and intracellular calcium propagation that could be 
followed from the cell body to the periphery (Figure 17B). The fvERM outgrowing 
cells responded to mechano-stimulation by increasing their [Ca2
+
]i in a monophasic 
manner (Figure 17C,D). The parts of interest are shown by colored arrows 
superimposed onto the morphology image. The colors correspond to the traces showing 
the time courses of the 360⁄380 ratio, proportional to [Ca2+]i for the selected areas. The 
resting levels, the increase in 360/380 ratio upon stimulation and the amplitudes of the 
ratio of the responses corresponding to the resting levels and the changes in [Ca2
+
]i can 
all visualized in Figure 17. 
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Figure 17. Intracellular propagation of calcium signal upon mechanical 
stimulation in fvERM outgrowing cells from PDR 
A. A glass pipette was used for mechanical stimulation of cells. B. Regions of interest 
(ROIs) are presented in different colors to which the traces on panel C and D 
correspond. C. The intracellular calcium concentration changes in time are marked with 
colored traces before and after the mechanical stimulation, the different colors 
corresponding to the regions of the cell marked accordingly. D. Enlarged region of the 
traces in C showing that calcium increase starts in the cell region marked in blue and 
then propagates with a time delay to the cell regions marked in red-green and then 
yellow. E. The intracellular calcium concentration distribution shown as color-coded 
images, corresponding to the four selected instants marked in C with asterisk. 
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6. DISCUSSION 
 
The importance of the LESCs in corneal biology and regeneration is well known, the 
absence or removal of which can cause defective corneal regeneration
47,48
. In humans, 
several diseases are known with acquired or genetic loss of LESCs, such as Steven 
Johnson syndrome, chronic limbitis, ocular pemphigoid or chronic inflammation-
caused LESCD. Inflammatory processes with uncontrolled neovascularization very 
likely change the environment in such a way, that the small niches of stem cells become 
non-functional
4,13,49
. This process leads to decreased epithelial differentiation and 
transparency of the cornea, resulting in a serious and painful disease with subsequent 
loss of vision
50
. The treatment of LESCD is based upon the replacement of stem or 
progenitor cells in the limbus, with the more appropriate ex vivo culturing and proof-of-
functionality of the LESCs becoming widely accepted today
51
. Other cells such as 
embryonic stem cells, bone-marrow and Wharton jelly-derived stem cells have been 
attempted for LESCD treatment in animal models with relatively good outcomes as 
well
52,53
. Unlike the new directives, most of the cell therapies used so far culture the 
limbal epithelial cells on 3T3 mouse feeder fibroblasts supplemented with FCS-
containing medium
54
, therefore, causing risk for murine (animal) viral transmission, 
prions and contamination with other unknown factors
55,56
. Although the overall success 
rate of the cell therapies has been reported to be 76%
56
 with replacement of corneal 
epithelial cells, the recovery of stemness is still unknown
52
. According to the new 
directives and directions for quality, safety and efficacy of advanced-therapy medicinal 
products (ATMPs), animal material-free methods would be more plausible and accurate 
way to go
57,58
, however, the right quantity and phenotype of the cells needed for it has 
not been determined yet. The latter is crucial in stem cell-based therapies, since the 
purity of the product (the percentage of stem cells within the cell culture) determines 
the outcome
21,56
. As mentioned earlier, the LESCs continuously replace the corneal 
epithelium, but during the epithelial expansion and differentiation they lose their 
multipotency
59
; therefore, it is important to distinguish between niche cells, LESCs, 
TAMs and CECs within the cell culture used for therapy. One of the key features in cell 
therapy products is the amount of LESCs or cells which are capable of keeping their 
stemness after being transplanted. 
In the maintenance of stemness, the SRY-related HMG-box family member SOX is 
important. In our LESC cultures, SOX9 expression was up-regulated, while SOX6 was 
down-regulated, indicating no chondrogenic differentiation but high proliferative 
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capacity of the LESCs. Similarly, Wnt2, Wnt6, Wnt11 and Wnt16b have been reported 
to be typically expressed in the limbal region and to be important for the LESCs 
proliferation
60
. We could confirm that the expression of WNT1 and WNT5A was up-, 
while WNT3A was down- regulated in our LESCs, along the wider lines of the results 
mentioned above. The limbal epithelial crypt cells express S100A4 and A9 proteins
61
; 
our LESCs, the S100A4 was down-regulated, indicating they are not crypt cells. We 
could not confirm a difference between the LESCs and differentiated CECs in the other 
known or putative LESC markers
62
, such as CXCL12, COL2A, ISL1, FOXA2, NCAM1, 
ACAN, GJB1 and MSX1. In our dataset, only FOXA1 was up-regulated and GJA1 was 
down-regulated, the latter also being known as negative marker for LESCs
63
 (Figure 
5). At protein level, the LESCs were different from the CECs in their higher positivity 
for CD146/MCAM, CD47 and CD117/c-kit, showing a pattern typical for stem cells 
and higher multipotency. The phenotype analysis demonstrated that the classical MSC 
markers, such as CD90/Thy-1 and CD73 are not good enough to differentiate between 
LESCs and CECs. The CAMs and integrins are important for attachment to ECM 
proteins, and their expression pattern is typical for the tissue of origin. Indeed, the 
integrin expression is able to define the cell phenotype and seems to be useful in 
classifying MSCs from various tissues besides the well-known MSC markers we have 
reported before
57
. The results of our gene array data analysis strengthen the fact that the 
LESCs cultured in medium containing human serum as the only growth supplement can 
keep their integrin and CAM pattern that relates them to their limbal tissue phenotype 
(Figure 13). 
 Not only the attachment, but the ECM breakdown is important in the initial 
steps of tissue healing and remodeling
64,65
. MMPs play a key role in this process, which 
were up-regulated in the LESCs, and their pattern implicates a preferred degradation of 
collagens to rebuild the ECM
64
. Along the upregulated MMP genes, the limbal basal 
membrane’s laminin and vitronectin66, 67 and their genes were also up-regulated in the 
LESCs (Figure 8). Wound healing can often lead into angiogenesis, which can have a 
very important and controllable pathological role in the limbus
41,65,68,69
. Fibronectin 
plays a key role in the de novo formation of new vessels, sprouting and differentiation 
of vessel wall resident and endothelial progenitor/stem cells into endothelial cells
70-72
. 
Beside the most upregulated fibronectin gene, several possible members of 
angiogenesis were also detected (Figure 9).  
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The two highest up-regulated gene products found in our LESCs seem to have an 
opposite effect on the angiogenesis pathway: IL-1β can induce-, while CXCL10 can 
inhibit the formation of new vessels
73-77
. Furthermore, CXCL10 has been found to be 
expressed by human limbal epithelial progenitor cells
78
, while its absence decreased the 
level of IL-6 in mice corneas
79
. During wound healing, TGFB1 is highly expressed and 
it can induce VEGF expression which was also up-regulated in the LESCs, capable of 
provoking angiogenesis in a damaged tissue
80,81
. Similar to the VEGF, ET-1 has many 
direct and indirect angiogenic effects - it stimulates endothelial cells and fibroblasts to 
produce pro-angiogenic proteases
82,83
 (Figures 7 and 9). At gene and at protein level as 
well, we observed IL-6 and IL-8 secretion by the LESCs in culture (Figure 12). IL-6 
and IL-8 play a role in inflammation, angiogenesis and MSC differentiation
84
 (Figures 
10 and 11). Our results indicate that both pro- and anti-angiogenic genes are expressed 
at the same time or in a balanced fashion in LESCs, maintaining an avascular state in 
the normal cornea. Loss of this control can be initiated by either a decreased production 
of anti-angiogenic molecules or increased production of pro-angiogenic and 
inflammatory factors. Although transplantation of LESCs has been known to suppress 
corneal inflammation and angiogenesis, the molecular mechanism how LESCs 
participate in the processes has not yet been fully understood
11,52,68,85,86
. Limbal niche 
cells have been found to have a differentiating ability towards angiogenic progenitors 
and inhibition of vascular endothelial differentiation of LESCs
85
. 
 Overall, our gene selection and networks are somewhat different from the well-
known canonical pathways described so far, because they were generated de novo and 
were based on own and already published data from networks in the literature. It 
remains to be further investigated and confirmed whether these pathways reflect in the 
same manner at protein level both ex vivo and in situ, thus providing an alternate or 
more specific way to select for LESCs and, at the same time, standardize the cell 
cultures used as ATMP in the near future. 
 Neovascularization is a key mediator of corneal diseases, but it is also an 
important player in PDR. Many cell types have been shown to have a direct or indirect 
function in angiogenesis. In the retina, the EPCs have been described as key members 
of retinal neovascularization formation
87-89
 as well as the pathology of DR
90-94
. 
Nevertheless, the real phenotype of the cells found in fvERMs and capable of growing 
out of the membranes is not clear; in particular, it is not known what type of cells 
initiate angiogenesis in PDR. The EPCs express hematopoietic stem cell- and 
monocyte- surface markers such as CD31, CD34, CD45, CD14 and VEGFR2. Our ex 
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vivo cultured fvERM and primary hRPE cells did not show an EPC - or retinal 
endothelial cell phenotype
95
, although they expressed CD14, CD31 and CD34 to certain 
levels. Interestingly, the surface marker expression pattern of the primary hRPE cells 
appeared to be the closest to an EPC phenotype
96
, although no CD45 positivity could be 
detected on their surface, meaning no haematopoietic origin of these cells
97
. The 
CD117/c-kit marker is characteristic of retinal progenitor cells
98-100
 and angiogenic 
cells
89,101
, which to a certain extent was the case with our primary hRPE, but it was 
absent from the fvERM outgrowing cells (Figure 14). 
 CD73, CD90 and CD105 are known as putative MSC (fibroblast-like) 
markers
57
; while CD73 and CD90 were present on both cell types, CD105 did not reach 
a sufficient expression level to qualify the cells as MSCs. CD73 has been described as a 
retinal photoreceptor progenitor marker in mice
102-104
 and found on human RPE cells as 
well
105
. ABCG2, often referred as a stem cells- and retinal progenitor cells marker, was 
expressed at a low level on the fvERM outgrowing cells (<1%), while it was much 
higher on the primary hRPE cells (17.63+15.09%)
106
. The immune status of the cells is 
also very important - no HLA-G expression of this immunosuppressive marker could be 
detected on both cell types, while HLA-DR expression was very low on these cells
107-
110
 (Figure 14).  
 CAMs and integrins play a key role in the cell-cell and cell-ECM contacts 
during immune response. In PDR, the cellular and soluble forms of ICAM-1 have been 
frequently shown in epiretinal membranes, serum or vitreous
111-114
 and diabetic 
fibrovascular membranes
115
 of patients. Our fvERM outgrowing cells increased the 
ICAM-1 expression upon TNFα pro-inflammatory stimulus, similar to the primary 
hRPE cells
97,116-119
, meaning that these cells function as activated epithelial cells for 
leukocyte adhesion
120,121
. CD11a (LFA-1) interacts to ICAM-1 and plays a key role in 
lymphocyte co-stimulation. No CD11a (LFA-1) positivity was observed in both cell 
types under basal conditions. Previously, CD29/ integrin β1122, CD51/integrin αV and 
CD44/HCAM have been described to be present on the surface of hRPE cells
120,123,124
, 
but we detected more positivity for integrin α1 and integrin α2 in the primary hRPE cell 
cultures compared to the studies published to date
123
. The integrin pattern of our cells 
differed in their CD18/integrin β2 and CD51/integrin αV expression. The fvERM 
outgrowing cells expressed low levels of the α-subunit-containing integrins, besides a 
reported expression of integrin α4 in DR123,125. Interestingly, the presence of integrin β2 
subunit has been considered an important factor in RPE-T cell interactions
126
 (Figure 
14). 
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The CD146 expression on fvERM outgrowing- or primary hRPE cells was described 
the first time by our group. The cells expressed low levels of CD146 of this generally 
considered MSC marker
57
, but also a novel endothelial biomarker, which plays an 
essential role in the angiogenesis by interacting directly with VEGFR2 found on 
endothelial cells
96
. In addition, CD146 has been accepted as a marker of a new EPC 
subset as well
97
. Although no data exists about positivity of fvERM outgrowing- and 
primary hRPE cells for CD166, cancer-, stem- and retinal endothelial- cells have been 
shown to express it
94
. 
The PDGF receptor and its subunits have already been detected on RPE 
cells
127,128
 and investigated in ERMs of patients with proliferative vitreoretinopathy 
(PVR)
129. The PDGFRβ subunit has been found to be less frequent than the PDGFRα 
subunit
129,130
. The PDGF produced by hRPE cells can act as autocrine growth factor
131
 
and influence wound healing and migration of these cells towards wounds; the 
interaction of the ligand with its receptor seems to be exaggerated during wound repair 
and, therefore, ERM formation. Indeed, cells isolated from ERMs removed during 
vitrectomy for PVR show expression of PDGF receptor and are usually identified as 
RPE cells
95
 (Figure 14).  
The presence of TNFα changed the CXCR4 expression in fvERM outgrowing 
cells, similar to how it acts upon HUVEC or Langerhans cells
132
. IL-1β or TNF-α can 
increase the CXCR4 mRNA expression in RPE cells
132
, which indicates that fvERM 
outgrowing cells are not the migrating cells in DR in response to increased local 
SDF1α94, nor that cell migration occurs via the well-known SDF1α-CXCR4 axis 
(Figure 16).  
VEGFR2 plays a crucial role in endothelial differentiation of progenitors 
mediated by pro-angiogenic or inflammatory signals. We investigated the possible 
expression of VEGFR2 on fvERM outgrowing cells upon stimulation with TNFα and 
found no expression of this receptor under such treatment (Figure 16). Despite this 
finding, cells that are not directly involved in the angiogenesis can secrete pro- or anti- 
angiogenic factors during cell differentiation to either support- or inhibit- vessel 
formation in their microenvironment, respectively. In PDR the presence of TNFα in the 
vitreous is an important marker of the disease
113,133
.  
In vitro, the fvERM cells secreted MCP-1/CCL-2 and IL-8/CXCL-8 upon TNFα 
treatment - phenomenon which has been observed in ARPE -19 cells and primary hRPE 
cells also. Besides TNFα, IL-1β and co-culturing with T lymphocytes have all been 
shown to induce IL-6, IL-8 and MCP-1 secretion in ARPE-19 cells
134-136
; in addition, 
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TLR3 ligands have been shown to have the same effect on hRPE cells
119
. MCP-1 is 
chemokine for monocytes and can induce apoptosis in hRPE cells
137
. Furthermore, 
MCP-1 has been detected in the aqueous humor of patients with diabetic retinopathy
138
 
and its level was higher in a rodent model of this disease
139
. MMPs play a key role in 
the first stage of cell migration, connective tissue remodeling and degradation of basal 
lamina and surrounding extracellular matrix (ECM) during neovascularization
140
. 
MMP-9 appeared, while TIMP-1 levels increased upon TNFα treatment of fvERM 
outgrowing cells. Although the MMP-9 level has been previously determined in 
PDR
141-143
, nothing is known about its level in healthy retina
142
. TIMP-1 and TIMP-2 
have both been measured in the vitreous of patients with PDR
144
 - increased levels of 
TIMP-1 have been associated with the disease
142,144-146
. The fvERM outgrowing cells 
expressed and secreted a basal level of TIMP-1, probably serving as a counter-coup to 
angiogenesis via inhibiting MMPs
147
 (Figure 15).  
PTX3 has many immunological activities in innate immunity, mainly in the 
inhibition of the uptake of apoptotic cells by antigen presenting cells (APCs)
148,149
. 
TNFα could induce PTX3 in ARPE-19 cells150, but no such data have been shown in 
primary hRPE and fvERM outgrowing cells. EG-VEGF/PK-1 is a novel selective 
angiogenic mitogen with a special pro-survival effect in different cell types
151
, 
including endothelial cells, dendritic cells (DCs), monocytes and neutrophils; no reports 
have been made about its presence in primary hRPE and fvERM outgrowing cells. 
Interestingly, PK1 and PK2 have been shown to induce monocyte differentiation and 
activation, suggesting an immunomodulatory function at local sites of 
inflammation
152,153
 (Figure 15).  
Hypoxic conditions stimulate Serpin E1/PAI-1 by hRPE
154
. Serpin E1/PAI-1 is 
a principal inhibitor of tissue plasminogen activator (tPA) and urokinase. PAI-1 could 
facilitate retinal angiogenesis in a model of oxygen-induced retinopathy
155
. Serpin 
F1/PEDF plays a very important anti-angiogenic and anti-oxidant role in the eye
156
. It 
has been found in the vitreous
157
 and serum
158
 of patients with PDR (Figure 15).  
IGFBPs have been detected in the vitreous of patients suffering from 
neovascular ocular diseases
159
. In particular, IGFBP-2 and IGFBP-3 appear to be potent 
inhibitors of IGF-I and IGF-II activity in Muller cells
160
 and inhibitors of cell growth of 
retinal endothelial cells
161
. Overexpression of ET-1 can lead to retinal edema, 
degeneration and neuronal death in animal models
162,163
. Dipeptidyl peptidase-4 (DPP4) 
is an important player in glucose metabolism, but it has also been described for its role 
in immune regulation and apoptosis. Thrombospondin-1 (TSP-1) is a natural inhibitor 
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of angiogenesis. High levels of TSP-1 have been detected in drusen found in early stage 
age-related macular degeneration
164
. The existence of TSP-1 in the vitreous has been 
controversial and sometimes reported as present
165
 or absent
166
 in PDR patients (Figure 
15). 
So far, the origin of the cells found in the fvERMs has not been well understood. 
There is also lack of knowledge regarding the fvERMs cells specific features, including 
the Ca
2+
-signaling pathways. The knowledge of Ca
2+
 dynamics is important toward 
understanding cell biology. Mechanical force modulates a wide array of cell 
physiological processes. Cells from diverse tissues detect mechanical load signals by 
similar mechanisms, but respond differently. The diversity of responses reflects the 
genotype of the cell and the mechanical demands of the resident tissue. It has been 
shown that hyperglycemia alters the tight control of [Ca2
+
]i dynamics in retinal cells 
and may lead to the development of DR
167
. Calcium signaling upon mechanical 
stimulation has been previously demonstrated in human corneal endothelial-
168
, RPE- 
cells
169
, rat retinal astrocytes and Müller cells170. Mechanosensory function of Müller 
cells in the retina upon application of tractional force to the living retina showed that 
Müller cells respond to retinal stretch both with fast changes, as evidenced by transient 
[Ca2
+
]i increases, and with slower changes in protein expression
171
. A model for Ca
2+
 
waves in networks of glial cells has been studied
172
 which confirms the importance of 
Ca
2+
 signaling measurements. It has also been shown that calcium signaling mediates 
mechanically induced human MSC proliferation
173
. The calcium signaling has been 
also recognized as a regulator of hematopoiesis
174
 - the application of shear stress to 
hematopoietic progenitor cells has been shown to stimulate hematopoiesis
175
. Store-
operated Ca
2+
 entry has been shown to be expressed in human endothelial progenitor 
cells
176
. [Ca
2+
]i stores are essential for injury-induced Ca
2+
 signaling and re-
endothelialization
177
 (Figure 17). 
An unwanted consequence of the appearance of fibrovascular membranes in PDR 
is the tractional force these membranes can impose upon the retina, which can 
eventually lead to retinal detachment. Mechanical stimulation of the cells in the 
membranes or the retina can result in [Ca
2+
]i changes that can propagate through the 
cells as intercellular waves. Generation of such calcium waves occurs by the release of 
calcium from internal stores. The waves do not evoke changes in the cell membrane 
potential, but may constitute a pathway for extraneuronal signaling
178
. Along that line, 
isolated retinal ganglion cells can respond directly to mechanical deformation with 
pannexin-mediated ATP release and auto-stimulation of the P2X7 receptors
179
. 
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Furthermore, stimulation of RPE cells with mechanical stress can upregulate MMP-2 
and fibronectin (FN) expression through activation of the p38 pathway
180
. 
Overall, we could isolate and cultivate cells from fvERMs obtained from patients 
with PDR and show their proliferative potential, phenotype, pro-angiogenic activity and 
response to mechano-stimulation. Our results suggest that these cells play a role in the 
pathomechanism of abnormal neovascularization as being activated by pro-
inflammatory stimuli. 
 
 67 
 
7. SUMMARY 
The human eye as an organ possesses great potential for regeneration and cell therapy, 
in particular, its corneal surface which contains LESCs. Identifying molecular markers 
and upstream regulators in the LESCs using genome-wide microarray transcriptional 
profiling, as well as verification of those at protein expression level can provide a better 
identification and more specific understanding of the signaling molecules associated 
with these cells, therefore, better application in ocular surface disease therapy. 
Although the eye is composed of many cell types with stem cell-like properties, altered 
cellular environments or disease states can tip the balance towards pro-inflammatory 
and fibrovascular processes as is the case with PDR. The surface marker phenotype of 
the cells obtained from human fvERMs in PDR has not been fully characterized nor the 
role these cells play in immunity and angiogenesis. 
Genome-wide microarray transcriptional profiling compared the LESCs to 
differentiated human CECs. More than 2 fold increase and decrease in expression could 
be found in 1830 genes between the two cell types. A number of molecules functioning 
in cellular movement (381), proliferation (567), development (552), death and survival 
(520), and cell-to-cell signaling (290) were detected having top biological functions in 
LESCs and several of these were confirmed by flow cytometry surface protein analysis. 
Custom-selected gene groups related to stemness, differentiation, cell adhesion, 
cytokines and growth factors as well as angiogenesis could be analyzed. The results 
show that LESCs play a key role not only in epithelial differentiation and tissue repair, 
but also in controlling angiogenesis and extracellular matrix integrity. Some pro-
inflammatory cytokines were found to be important in stemness-, differentiation- and 
angiogenesis-related biological functions: IL-6 and IL-8 participated in most of these 
biological pathways as validated by their secretion from LESC cultures. 
The cultivated fvERMs formed proliferating cell monolayers when cultivated ex vivo. 
These cells were negative for some endothelial cell markers (CD31, VEGFR2), 
partially positive for hematopoietic- (CD34, CD47) and mesenchymal stem cell 
markers (CD73, CD90/Thy-1, PDGFRβ) and negative for CD105. The CD146/MCAM 
and CD166/ALCAM, which have not been previously reported in cells from fvERMs, 
showed low and high expression levels, respectively. Secretion of 11 angiogenesis-
related factors (DPPIV/CD26, EG-VEGF/PK1, ET-1, IGFBP- 2 and 3, IL-8/CXCL8, 
MCP-1/CCL2, MMP-9, PTX3/TSG-14, Serpin E1/PAI-1, Serpin F1/PEDF, TIMP-1 
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and TSP-1) were detected upon activation of fvERM cells by TNFα. Mechano-
stimulation of the outgrowing cells induced intracellular calcium propagation 
representing their functional viability and the role it can have in fvERM-related 
tractional retinal detachment. 
Overall, new biological functions or signaling-related pathways were identified in 
human LESCs which play a crucial role in cellular adhesion and migration, epithelial 
differentiation and tissue repair, as well as angiogenesis and extracellular matrix 
integrity. A method for isolating and cultivating cells coming from fvERMs from PDR 
was established and characterization of their origin as mixed or not pure hematopoietic, 
mesenchymal or epithelial was achieved. The fvERM outgrowing cells had a clear 
proliferative potential, were capable of releasing pro-inflammatory and angiogenic 
molecules upon stimulation with TNFα and showed functionality and viability reflected 
through calcium dynamics upon mechano-stimulation, which can serve as a study 
model for tractional forces present in fvERMs in PDR ex vivo. 
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